Core Insights - Equillium, Inc. announced changes to its Board of Directors and senior leadership to enhance its focus on advancing EQ504, a novel aryl hydrocarbon receptor modulator for treating severe inflammatory diseases [2][3][4] Corporate Governance Changes - Effective October 1, 2025, Equillium implemented changes to its corporate governance structure [3] - Stephen Connelly, Ph.D. has been promoted to President while retaining his role as Chief Scientific Officer [8] - Daniel M. Bradbury transitioned from Executive Chairman to Chairman of the Board [8] Termination of Collaboration - Equillium has terminated its collaboration and license agreement with Biocon regarding itolizumab as of September 30, 2025, indicating no further intention to develop this product [4] Product Development Focus - EQ504 is an investigational aryl hydrocarbon receptor modulator designed to treat severe inflammatory diseases with a non-immunosuppressive mechanism [5] - The drug aims for targeted delivery methods, including enteric coating for ulcerative colitis and inhaled formulations for inflammatory lung diseases [5] Company Overview - Equillium is a clinical-stage biotechnology company focused on developing therapeutics for severe autoimmune and inflammatory disorders, leveraging its expertise in immunobiology [6]